


CLAIMS

We Claim:

1. A compound having the structure of Formula (I):



Formula (I);

wherein:

- R¹ is H or C₁₋₆alkyl;
- R² is C₁₋₆alkyl;
- R³ is H or C₁₋₆alkyl;
- R⁴ and R⁵ are independently selected from H and C₁₋₆alkyl;
- each R⁶ is independently selected from C₁₋₆alkyl, halogen, -CN, C₁₋₆haloalkyl, -OR⁷, -C(O)NR⁸R⁹, C₃₋₆cycloalkyl, C₂₋₉heterocycloalkyl, -C₁₋₆alkyl(C₂₋₉heterocycloalkyl), and C₂₋₉heteroaryl, wherein C₃₋₆cycloalkyl, C₂₋₉heterocycloalkyl, -C₁₋₆alkyl(C₂₋₉heterocycloalkyl), and C₂₋₉heteroaryl are optionally substituted with one, two, or three groups independently selected from halogen, C₁₋₆alkyl, C₁₋₆haloalkyl, and C₁₋₆alkoxy;
- each R⁷ is independently selected from H, C₁₋₆alkyl, C₁₋₆haloalkyl, and C₃₋₆cycloalkyl;
- each R⁸ and R⁹ is each independently selected from H, C₁₋₆alkyl, C₃₋₆cycloalkyl, aryl, and heteroaryl; or R⁸ and R⁹, together with the nitrogen to which they are attached, form a heterocycloalkyl ring optionally substituted with one, two, or three R¹⁰;
- each R¹⁰ is independently selected from halogen, C₁₋₆alkyl, C₁₋₆haloalkyl, oxo, -CN, and C₃₋₆cycloalkyl;
- n is 0, 1, 2, 3, or 4; and
- p is 0 or 1;


or a pharmaceutically acceptable salt or solvate thereof.

2. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein p is 0.
3. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein p is 1.

4. The compound of claim 3, or a pharmaceutically acceptable salt or solvate thereof, wherein R^4 and R^5 are H.
5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt or solvate thereof, wherein R^3 is H.
6. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt or solvate thereof, wherein R^3 is C_{1-6} alkyl.
7. The compound of claim 6, or a pharmaceutically acceptable salt or solvate thereof, wherein R^3 is $-CH_3$.
8. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt or solvate thereof, wherein R^2 is $-CH_3$.
9. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt or solvate thereof, wherein each R^6 is independently selected from C_{1-6} alkyl, halogen, $-CN$, C_{1-6} haloalkyl, $-OR^7$, C_{3-6} cycloalkyl, C_{2-9} heterocycloalkyl, and C_{2-9} heteroaryl, wherein C_{3-6} cycloalkyl, C_{2-9} heterocycloalkyl, and C_{2-9} heteroaryl are optionally substituted with one or two groups independently selected from halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, and C_{1-6} alkoxy.
10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt or solvate thereof, wherein each R^6 is independently selected from C_{1-6} alkyl, halogen, $-CN$, C_{1-6} haloalkyl, $-OR^7$, and C_{3-6} cycloalkyl.
11. The compound of any one of claims 1-10, or a pharmaceutically acceptable salt or solvate thereof, wherein each R^7 is independently selected from C_{1-6} alkyl and C_{1-6} haloalkyl.
12. The compound of any one of claims 1-10, or a pharmaceutically acceptable salt or solvate thereof, wherein each R^6 is independently selected from C_{1-6} alkyl, halogen, $-CN$, and C_{1-6} haloalkyl.
13. The compound of claim 12, or a pharmaceutically acceptable salt or solvate thereof, wherein each R^6 is independently selected from halogen and C_{1-6} haloalkyl.
14. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1 or 2.
15. The compound of claim 14, or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1.
16. The compound of claim 14, or a pharmaceutically acceptable salt or solvate thereof, wherein n is 2.
17. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt or solvate thereof, wherein n is 0.

18. The compound of any one of claims 1-17, or a pharmaceutically acceptable salt or solvate thereof, wherein R^1 is H.

19. A compound having the structure of Formula (II):



Formula (II);

wherein:

R^1 is $-R^{14}$, $-OR^3$, $-SR^4$, $-S(O)_2R^4$, $-N(R^4)(R^5)$, $-NH(R^4)$, or $-C\equiv C-(CR^6R^7)-R^8$;

$R^{1'}$ is C_{3-6} cycloalkyl, C_{2-9} heterocycloalkyl, or C_{2-9} heteroaryl, wherein C_{3-6} cycloalkyl, C_{2-9} heterocycloalkyl, or C_{2-9} heteroaryl are optionally substituted with

one, two, or three groups independently selected from halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, and C_{1-6} alkoxy;

each R^2 is independently selected from C_{1-6} alkyl, halogen, $-CN$, C_{1-6} haloalkyl, $-C_{1-6}$ alkyl(heterocycloalkyl), $-OR^{17}$, and $-C(O)NR^{18}R^{19}$;

R^3 is $-(CR^6R^7)_m-R^8$, $-(CR^6R^7)_p-Y-(CR^6R^7)_q-R^8$, or $-(CR^6R^7)_t-C_{3-6}$ cycloalkyl- R^8 ;

R^4 is $-(CR^6R^7)_m-R^8$, $-(CR^6R^7)_v-C(O)OH$, or $-(CR^6R^7)_p-Y-(CR^6R^7)_q-R^8$;

$R^{4'}$ is $-(CR^6R^7)_m-R^8$, $-(CR^6R^7)_p-Y-(CR^6R^7)_q-R^8$, $-C_{4-6}$ alkyl- $C(O)OH$, $-C_{3-6}$ cycloalkyl- $C(O)OH$, or $-C_{1-6}$ alkyl- C_{3-6} cycloalkyl- $C(O)OH$;

Y is $-O-$ or $-N(R^{22})-$;

R^5 is C_{1-6} alkyl or $-CH_2$ -phenyl optionally substituted with one, two, or three groups independently selected from halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, and C_{1-6} alkoxy;

each R^6 and R^7 is each independently selected from H, F, and C_{1-6} alkyl; or R^6 and R^7 , together with the carbon to which they are attached, form a C_{3-6} cycloalkyl ring;

R^8 is $-C(O)OR^9$, $-C(O)R^{10}$, or $-C(O)O-(CR^{12}R^{13})-OC(O)R^{11}$;

$R^{8'}$ is $-C(O)OR^{9'}$, $-C(O)R^{10'}$, or $-C(O)O-(CR^{12}R^{13})-OC(O)R^{11}$;

R^9 is H or C_{1-6} alkyl;

$R^{9'}$ is C_{1-6} alkyl;

R^{10} is C_{1-6} alkyl or $-NHSO_2R^{21}$;

$R^{10'}$ is C_{2-6} alkyl or $-NHSO_2R^{21}$;

R^{11} is C_{1-6} alkyl or C_{1-6} alkoxy;

R^{12} and R^{13} is each independently H or C_{1-6} alkyl;

R^{14} is $-(CR^{15}R^{16})_m-R^8$ or $-(CR^6R^7)_p-Y-(CR^6R^7)_q-R^8$;

each R^{15} and R^{16} is each independently selected from H, F, and C_{1-6} alkyl;

each R^{17} is independently selected from H, C_{1-6} alkyl, C_{1-6} haloalkyl, and C_{3-6} cycloalkyl;

each R^{18} and R^{19} is each independently selected from H, C_{1-6} alkyl, C_{3-6} cycloalkyl, aryl, and heteroaryl; or R^{18} and R^{19} , together with the nitrogen to which they are attached, form a heterocycloalkyl ring optionally substituted with one, two, or three R^{20} ;

each R^{20} is independently selected from halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, oxo, -CN, and C_{3-6} cycloalkyl;

R^{21} is C_{1-6} alkyl or C_{3-6} cycloalkyl;

R^{22} is H, C_{1-6} alkyl, or $-SO_2R^{23}$;

R^{23} is C_{1-6} alkyl;

m is 1, 2, 3 or 4;

n is 0, 1, 2, or 3;

p is 2, 3, or 4;

q is 1, 2, or 3;

t is 0, 1, or 2; and


v is 3 or 4;


or a pharmaceutically acceptable salt or solvate thereof.

20. The compound of claim 19, or a pharmaceutically acceptable salt or solvate thereof, wherein R^1 is $-OR^3$.
21. The compound of claim 19 or 20, or a pharmaceutically acceptable salt or solvate thereof, wherein R^3 is $-(CR^6R^7)_m-R^8$.
22. The compound of any one of claims 19-21, or a pharmaceutically acceptable salt or solvate thereof, wherein m is 1, 2, or 3.
23. The compound of any one of claims 19-22, or a pharmaceutically acceptable salt or solvate thereof, wherein each R^6 and R^7 is each independently selected from H and C_{1-6} alkyl, or R^6 and R^7 , together with the carbon to which they are attached, form a C_{3-6} cycloalkyl ring.
24. The compound of any one of claims 19-23, or a pharmaceutically acceptable salt or solvate thereof, wherein R^8 is $-C(O)OR^9$.
25. The compound of claim 24, or a pharmaceutically acceptable salt or solvate thereof, wherein R^9 is H.
26. The compound of claim 24, or a pharmaceutically acceptable salt or solvate thereof, wherein R^9 is C_{1-6} alkyl.

27. The compound of any one of claims 19-23, or a pharmaceutically acceptable salt or solvate thereof, wherein R^8 is $-C(O)R^{10}$.
28. The compound of claim 27, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{10} is $-NHSO_2R^{21}$.
29. The compound of claim 28, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{21} is C_{1-6} alkyl.
30. The compound of claim 28, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{21} is C_{3-6} cycloalkyl.
31. The compound of any one of claims 19-30, or a pharmaceutically acceptable salt or solvate thereof, wherein each R^2 is independently selected from C_{1-6} alkyl, halogen, and C_{1-6} haloalkyl.
32. The compound of any one of claims 19-31, or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1.
33. The compound of any one of claims 19-30, or a pharmaceutically acceptable salt or solvate thereof, wherein n is 0.
34. The compound of any one of claims 19-33, or a pharmaceutically acceptable salt or solvate thereof, wherein $R^{1'}$ is C_{3-6} cycloalkyl, C_{2-9} heterocycloalkyl, or C_{2-9} heteroaryl, wherein C_{3-6} cycloalkyl, C_{2-9} heterocycloalkyl, or C_{2-9} heteroaryl are optionally substituted with one or two groups independently selected from halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, and C_{1-6} alkoxy.
35. The compound of any one of claims 19-34, or a pharmaceutically acceptable salt or solvate thereof, wherein $R^{1'}$ is C_{3-6} cycloalkyl, C_{2-9} heterocycloalkyl, or C_{2-9} heteroaryl, wherein C_{3-6} cycloalkyl, C_{2-9} heterocycloalkyl, or C_{2-9} heteroaryl are unsubstituted.
36. The compound of claim 35, or a pharmaceutically acceptable salt or solvate thereof, wherein $R^{1'}$ is unsubstituted C_{3-6} cycloalkyl.
37. The compound of claim 35, or a pharmaceutically acceptable salt or solvate thereof, wherein $R^{1'}$ is unsubstituted C_{2-9} heterocycloalkyl.
38. The compound of claim 35, or a pharmaceutically acceptable salt or solvate thereof, wherein $R^{1'}$ is unsubstituted C_{2-9} heteroaryl.


The image displays 15 chemical structures of substituted 2-(2,2,2-trifluoroethoxy)benzoic acids. Each structure consists of a central benzene ring with a carboxylic acid group (-COOH) at position 1 and a 2-(2,2,2-trifluoroethoxy) group (-OCH2CF3) at position 2. The benzene ring is further substituted at various positions with different functional groups, including chlorine, trifluoromethyl, trifluoromethoxy, cyclopropyl, tetrahydrofuran, cyano, isoxazole, methyl, and fluorine. The structures are arranged in a grid-like pattern, with some structures having additional substituents on the piperazine ring or the trifluoroethoxy group.






acceptable salt or solvate thereof.

40. A compound selected from:



pharmaceutically acceptable salt or solvate thereof.

41. A compound selected from:



acceptable salt or solvate thereof.

42. A pharmaceutical composition comprising a compound of any one of claims 1-41, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient.
43. A method of treating pain in a patient comprising administering to the patient in need thereof a therapeutically effective amount of a compound of any one of claims 1-41, or a pharmaceutically acceptable salt or solvate thereof.
44. The method of claim 43, wherein the pain is neuropathic pain.
45. The method of claim 43, wherein the pain is inflammatory pain.
46. A method of treating a disease or disorder in a patient comprising administering to the patient in need thereof a therapeutically effective amount of a compound of any one of claims 1-41, or a pharmaceutically acceptable salt or solvate thereof, wherein the disease or disorder is selected from the group consisting of epilepsy/seizure disorder, multiple sclerosis, neuromyelitis optica (NMO), Tourette syndrome, Alzheimer's disease, and abdominal pain associated with irritable bowel syndrome.
47. The method of claim 46, wherein the disease or disorder is multiple sclerosis.
48. The method of claim 46, wherein the disease or disorder is Tourette syndrome.
49. The method of claim 46, wherein the disease or disorder is Alzheimer's disease.
50. The method of claim 46, wherein the disease or disorder is abdominal pain associated with irritable bowel syndrome.
51. A method of treating attention deficit and hyperactivity disorder (ADHD) in a patient comprising administering to the patient in need thereof a therapeutically effective

amount of a compound of any one of claims 1-41, or a pharmaceutically acceptable salt or solvate thereof.